Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy

Modern Rheumatology

Volumn 15, Issue 2, 2005, Pages 91-96

  Ogawa, Jun ^a   Harigai, Masayoshi ^a   Nagasaka, Kenji ^b   Nakamura, Takahiro ^c   Miyasaka, Nobuyuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Ome Municipal General Hospital   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Connective tissue disease (CTD); Logistic regression analysis; Pneumocystis pneumonia (PCP); Trimethoprim sulfamethoxazole

Indexed keywords

ALBUMIN; AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; METHOTREXATE; PREDNISOLONE;

ADULT ONSET STILL DISEASE; ALBUMIN BLOOD LEVEL; ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BEHCET DISEASE; COGAN SYNDROME; COMPLEX REGIONAL PAIN SYNDROME TYPE I; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DERMATOMYOSITIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; ERYTHEMA; HUMAN; INFECTION PREVENTION; KIDNEY DYSFUNCTION; KIKUCHI DISEASE; LEUKOPENIA; LOGISTIC REGRESSION ANALYSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MIXED CONNECTIVE TISSUE DISEASE; NAUSEA; PERIPHERAL LYMPHOCYTE; PNEUMOCYSTIS PNEUMONIA; POLYMYOSITIS; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; SARCOIDOSIS; SJOEGREN SYNDROME; STATISTICAL MODEL; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VASCULITIS; WEBER CHRISTIAN PANNICULITIS;

EID: 20444435539     PISSN: 14397595     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-004-0368-5     Document Type: Article

References (28)

1. Hughes WT. Pneumocystis carinii infection. An update. Medicine 1992;71:175-8.
2. Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 1990; 322:161-5.
3. Vogel CL, Cohen MH, Powell RD, DeVita VT. Pneumocystis carinii pneumonia. Ann Intern Med 1968;68:97-108.
4. Le Clair RA. Descriptive epidemiology of interstitial pneumocystic pneumonia. an analysis of 107 cases from the United States, 1955-1967. Am Rev Resp Dis 1969;99:542-7.
5. Walzer PD, Perl DP, Krogstad DJ, Rawson PG, Schultz MG. Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features. Ann Intern Med 1974;80:83-93.
6. Burke BA, Good RA. Pneumocystis carinii infection. Medicine (Baltimore) 1973;52:23-51.
7. Pisani RJ, Wright AJ. Clinical utility of bronchoalveolar lavage in immunocompromised hosts. Mayo Clin Proc 1992;67:221-7.
8. Hughes WT, Feldman S, Aur RJA, Verzosa MS, Hustu HO, Simone JV. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer 1975;36: 2004-9.
9. Liam CK, Wang F. Pneumocystis carinii pneumonia in patients with systemic lupus erythematosus. Lupus 1992;1:379-85.
10. Okada J, Kadoya A, Rana M, Ishikawa A, Iikuni Y, Kondo H. Efficacy of sulfamethoxazole-trimethoprim administration in the prevention of Pneumocystis carinii pneumonia in patients with connective tissue disease. Kansenshogaku Zasshi 1999;73:1123-9.
11. Godeau B, Perronne VC, Huong DLT, Guillevin L, Magadur G, Bandt MD, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: Report of 34 cases. J Rheumatol 1994;21: 246-51.
12. Porges AJ, Beattie SL, Ritchlin C, Kimberly RP, Christian CL. Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia. J Rheumatol 1992;19:1191-4.
13. Chechani V, Bridges A. Pneumocystis carinii pneumonia in patients with connective tissue disease. Chest 1992;101:375-8.
14. Kadoya A, Okada J, Iikuni Y, Kondo H. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol 1996;23:1186-8.
15. Godeau B, Mainardi JL, Thoraval FR, Hachulla E, Guillevin L, Du LTH, et al. Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis. Ann Rheum Dis 1995;54:991-4.
16. Bozzette SA, Finkelstein DM, Spector SA, Frame P, Powderly WG, He W, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:693-9.
17. Walzer PD. Pneumocystis carinii. In: Mandell GL, editor. Principles and practice of infectious disease, 5th ed. Philadelphia: Churchill Livingstone; 2000: P. 2781-95.
18. Schneider MME, Hoepelman AIM, Eeftinck Schattenkerk JKM, Nielsen TL, Graaf Y, Frissen JPHJ, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992;327:1836-41.
19. Feinberg JE, Sattler FR. Pneumocystis carinii pneumonia. In: Goldman L, Bennett JC, editors. Cecil textbook of medicine, 21st ed. Philadelphia: Saunders; 2000. p. 1877-83.
20. Bergin CJ, Wirth RL, Berry GJ, Castellino RA. Pneumocystis carinii pneumonia: CT and HRCT observations. J Comput Assist Tomogr 1990;14:756-9.
21. Gupta S, Dash SC, Sharma S, Agarwal SK, Bhowmik D, Wani M, et al. Pneumocystis carinii pneumonia: Role of high resolution computed tomography. JAPI 2002;50:726-8.
22. Yasuoka A, Tachikawa N, Shimada K, Kimura S, Oka S. (1-3) β-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol 1996;3:197-9.
23. Tuan IZ, Dennison D, Weisdorf DJ. Pneumocystis carinii pneumonitis following bone marrow transplantation. Bone Marrow Transplant 1992;10:267-72.
24. Boumpas DT, Paliogianni F, Anastassiou ED. Glucocorticosteroid action on the immune system: Molecular and cellular aspects. Clin Exp Rheumatol 1991;9:413-23.
25. Akaike H. Information theory and an extension of the maximum likelihood principle. In: Petrov BN, Csaki F, editors. 2nd International symposium on information theory. Budapest: Akademiai Kaido; 1973. p. 267-81.
26. Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: The role of hospital experience in diagnosis and mortality. Arthritis Rheum 1999;42:780-9.
27. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: Importance of viral load and T-cell immunity. Blood 2003;101:407-14.
28. Becker BN, Becker YT, Heisey DM, Leverson GE, Collins BH, Odorico JS, et al. The impact of hypoalbuminemia in kidneypancreas transplant recipients. Transplantation 1999;68:72-5.